- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00865254
Prize Reinforcement for Smoking Cessation
27 juin 2013 mis à jour par: David Ledgerwood, Wayne State University
Nicotine dependence is prevalent in society, cigarette smoking is associated with several known health risks, and most dependent individuals find it very difficult to stop smoking cigarettes.
The present study will test the efficacy of a behavioral smoking cessation treatment, prize-based contingency management, that has not undergone rigorous study with respect to smoking, it but has demonstrated efficacy in reducing use of other substances (e.g.
cocaine).
If efficacious, prize-based contingency management would add to our repertoire of efficacious smoking cessation treatments.
Aperçu de l'étude
Statut
Complété
Les conditions
Description détaillée
Contingency management (CM) treatments are efficacious in reducing substance use.
A relatively new approach, called prize-based CM, which uses prizes to reinforce substance abstinence, is effective in decreasing certain types of substance use, but its efficacy has not been evaluated in the treatment of cigarette smoking.
One purpose of the current study is to assess the efficacy of a prize reinforcement intervention for reducing cigarette smoking.
A second purpose is to test the differential efficacy of two schedules of reinforcement, using cigarette smoking as an exemplar.
We will randomly assign 110 patients to one of three conditions: 1) Standard treatment; 2) Traditional prize reinforcement; or 3) Early-treatment enhanced prize reinforcement.
Patients in each condition will receive counseling for their smoking based on current standard of care guidelines.
All patients will participate in a one-week baseline period, followed by a four-week intervention.
Throughout both phases, each patient will meet with a research assistant twice daily to provide carbon monoxide (CO) samples.
Patients in the prize reinforcement conditions will earn the chance to win prizes when they provide negative CO samples (i.e., < 6ppm).
They will also earn bonus draws if they provide negative cotinine samples (i.e., <100ng/ml) after weekends.
Patients in the Traditional CM condition will have at least a 50% chance of winning a prize for each negative sample with escalating chances for successive negative samples.
Patients in the Enhanced condition will have the opportunity to earn the same overall number of draws and magnitude of reinforcement, but the schedule of reinforcement will differ.
For the first week of the CM phase, these patients will have a 100% chance of winning prizes, but in the latter 3 weeks, overall probability of reinforcement will be decreased to 34%.
Patients will also undergo 2- and 6-month follow-up assessments.
Primary outcome measures will be longest duration of continuous abstinence and mean number of days of abstinence.
We predict that the prize reinforcement will reduce cigarette smoking to a greater extent than standard treatment.
We also predict that the Enhanced CM condition will lead to greater reductions in cigarette smoking relative to the Traditional CM condition, and that these changes may result in longer sustained abstinence from smoking throughout the study period.
Type d'étude
Interventionnel
Inscription (Réel)
84
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48207
- Wayne State University, Jefferson Avenue Research Clinic
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
13 ans et plus (Enfant, Adulte, Adulte plus âgé)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- A current Fagerstrom scale score of 6 or greater;
- Age 13 years old or older (Under age 18, parental consent is required);
- Able to read and understand English.
Exclusion Criteria:
- Have current severe, uncontrolled psychiatric disorders (i.e., acute suicidality or psychosis);
- Have current substance dependence, other than nicotine or caffeine dependence;
- Are in recovery for pathological gambling; or
- Are already participating in other behavioral or medication smoking cessation programs.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Traditional Contingency Management
Standard treatment plus prize based contingency management.
|
Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Prize draws result in incentives on an intermittent schedule (50% of draws are prizes).
Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
|
|
Expérimental: Early Enhanced Contingency Management
Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
|
Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4).
Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
|
|
Comparateur actif: Standard Treatment
Counseling and monitoring of smoking cessation.
|
Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Expired Carbon Monoxide
Délai: Baseline and treatment phases, 2-mont and 6-month follow up.
|
Baseline and treatment phases, 2-mont and 6-month follow up.
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Self-reported smoking.
Délai: Baseline, throughout treatment, 2-month and 6-month follow up.
|
Baseline, throughout treatment, 2-month and 6-month follow up.
|
|
Cotinine levels.
Délai: Baseline, throughout treatment, 2-month and 6-month follow up.
|
Baseline, throughout treatment, 2-month and 6-month follow up.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: David M Ledgerwood, Ph.D., Wayne State University
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 août 2007
Achèvement primaire (Réel)
1 juillet 2011
Achèvement de l'étude (Réel)
1 juillet 2011
Dates d'inscription aux études
Première soumission
17 mars 2009
Première soumission répondant aux critères de contrôle qualité
17 mars 2009
Première publication (Estimation)
19 mars 2009
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
28 juin 2013
Dernière mise à jour soumise répondant aux critères de contrôle qualité
27 juin 2013
Dernière vérification
1 juin 2013
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- RDA021839A
- R21DA021839 (Subvention/contrat des NIH des États-Unis)
- 1R21DA021839-01 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .